· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2012 / N 4 Анемия при хронической болезни почек: роль препаратов железа (список литературы) О.А. Эттингер, И.К. Зеновко, Г.Е. Гендлин Список литературы. 1. Fishbane S, Pollack S, Feldman HI. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 2009; 4: 57-61. 2. Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE.Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010 Jul;25(7):2368- 75. 3. Bernhardt WM, Wiesener MS, Scigalla P et al. Inhibition of prolylhydroxylases increases erythropoietin production in ESRD. J Am Nephrol 2010; 21: 2151–2156. 4. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319–333. 5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012; 2: 279–335. 6. World Health Organization. Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia. In: de Benoist B, McLean E, Egli I and M Cogswell (eds), 2008. 7. Fehr T, Ammann P, Garzoni D et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 2004; 66: 1206– 1211. 8. Шило В.Ю., Хасабов Н.Н. Анемия при хронической болезни почек. Лечащий врач 2008; 1: 25–31. 9. Deicher R, Hцrl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006; 36:301–309. 10. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12:1549–1557. 11. Deicher R, Hцrl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 2004; 19:521–524. 12. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Hцrl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of 16 anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2):ii1–ii47. 13. Tessitore N, Girelli D, Campostrini N et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996–4002. 14. Weiss G, Gordeuk VR . Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest 2005; 35(Suppl 3):36–45. 15. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and highfluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003; 18:370–377. 16. Besarab A. Evaluating iron sufficiency: a clearer view. Kidney Int 2001;60:2412– 2414. 17. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lьscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25):2436-48. 18. Fishbane S, Ungureanu VD, MaesakaJK. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534. 19. Auerbach M and Talib K Al. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney International 2008:73, 528–530. 20. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004;15:S107-S111. 21. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion. 2010 Mar;50(3):719-32. 22. Lyseng-Williamson KA, Keating GM.. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69:739-756. 23. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64:572–578. 16 24. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38:1090–1094. 25. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G . Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13:734–744. 26. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869–876. 27. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15:1623–1632. 28. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279–2289. 29. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21:120–124. 30. Drьeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212–2217. 31. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita K. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004;66:841–848. 32. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Nontransferrin- bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 2004; 15:1648–1655. 33. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18:1272–1280. 34. Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Hцrl WH, Fцdinger M, Sunder-Plassmann G, Vychytil A. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 2005; 68:2814–2822. 16 35. DruekeTB, Locatelli F, Clyne N . Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084. 36. Pfeffer MA, Burdmann EA, Chen CY. . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032. 37. Singh AK, Szczech L, Tang KL. . Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098. 38. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi- Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA; TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20;124(25):2903-8. 39. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471–530. 40. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623–1632. 41. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070– 3080. 42. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients0 Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975–984. 43. Hцrl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikstrom B Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant 2005; 20(Suppl 3):iii25–iii32. 16    [ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]